SomaLogic

SomaLogic, Inc. is a commercial-stage proteomics company, which built an integrated proteomics platform for robust, high throughput proteomics analysis, research and clinical applications. The company was founded by Larry Gold in 2000 and is headquartered in Boulder, CO.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

SomaLogic reports mixed Q4 results, eyes growth through innovation

SomaLogic navigated a mixed financial performance in Q4 2022, focusing on cost management.
The company is strengthening its position in the life sciences sector with innovative products.
Challenges lie in leadership transitions and balancing expenses with growth investments.
Opportunities abound in strategic collaborations, product launches, and market expansion.

SomaLogic reports Q1 revenue growth amid margin challenges

SomaLogic's Q1 performance reflects revenue growth initiatives amidst financial challenges.
Strategic partnerships, expansion plans, and product launches position the company for future growth.
Addressing margin issues and optimizing expenses are critical for achieving profitability and meeting revenue targets.

SomaLogic reports robust Q2 revenue growth, eyes international partnerships

SomaLogic's Q2 2023 performance reflects strong revenue growth and improved cost management, yet challenges persist in achieving profitability.
Strategic strengths include experienced leadership, international expansion, and partnerships driving growth opportunities in the life sciences sector.
Maintaining operational rigor, enhancing margins, and leveraging cash reserves position SomaLogic for sustainable growth and market leadership.

SomaLogic reports revenue growth and strategic merger for future growth

SomaLogic's Q3 2023 performance showed revenue growth and cost management improvements, with a strong cash position. Strategic partnerships and merger offer growth opportunities.
Challenges include revenue decline on a GAAP basis and ongoing EBITDA losses. Opportunities lie in new indications, geographic expansion, and biopharma performance drivers.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Standard BioTools Inc

Stockholder Approval Represents Key Milestone Toward Completion of Standard BioTools Transaction Combination Will Create a Diversified Leader in Life Sciences Tools BOULDER, Colo. , Jan. 4, 2024 /PRNewswire/ -- SomaLogic, Inc. (Nasdaq: SLGC) ("the Company"), a leader in proteomics technology, today announced that, based on the preliminary vote count provided by its proxy solicitors following the Company's Special Meeting of Stockholders (the "Special Meeting") held earlier today, SomaLogic stockholders voted to approve the transaction with Standard BioTools Inc. (Nasdaq: LAB) ("Standard BioTools").

SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting

NEW YORK--(BUSINESS WIRE)--Madryn Asset Management, LP (collectively with its affiliates, “Madryn” or “we”), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. (“SomaLogic” or the “Company”) (Nasdaq: SLGC), is demanding the Company finally answer key questions related to its repeated adjournments of the Special Meeting of Shareholders (the “Special Meeting”) pertaining to the proposed merger (the “Proposed Merger” or the “Transaction”) with Standard BioTools Inc.

Madryn Asset Management Demands SomaLogic's Board Address Repeated, Unprecedented Adjournments of Tainted Special Meeting

NEW YORK--(BUSINESS WIRE)--Madryn Asset Management, LP (collectively with its affiliates, “Madryn” or “we”), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. (“SomaLogic” or the “Company”) (Nasdaq: SLGC), today issued the below statement regarding today's multiple adjournments of the Special Meeting of Shareholders (the “Special Meeting”) related to the proposed merger (the “Proposed Merger” or the “Transaction”) with Standard BioTools Inc. (“Standard BioTools”).

Madryn Asset Management Addresses SomaLogic's Apparent Failure to Obtain Requisite Shareholder Support for the Proposed Merger with Standard BioTools

NEW YORK--(BUSINESS WIRE)--Madryn Asset Management, LP (“Madryn Asset Management” and, collectively with its affiliates, “Madryn”), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. (“SomaLogic” or the “Company”) (Nasdaq: SLGC), today announced that Egan-Jones Proxy Services (“Egan-Jones”), an independent proxy advisory firm, has recommended shareholders vote AGAINST the proposed merger (the “Proposed Merger” or “Transaction”) with Standard BioTools Inc. (“Standa.

Proxy Advisory Firm Egan-Jones Recommends SomaLogic Shareholders Vote Against Proposed Merger with Standard BioTools

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Both Recommend SomaLogic Stockholders Vote "FOR" Proposed Merger with Standard BioTools BOULDER, Colo. , Jan. 2, 2024 /PRNewswire/ -- SomaLogic, Inc. (Nasdaq: SLGC) ("the Company"), a leader in proteomics technology, today sent the following open letter to stockholders urging them to vote "FOR" the value maximizing transaction with Standard BioTools.

SomaLogic Urges Stockholders to Maximize Value of Their Investment by Voting "FOR" Pending Merger with Standard BioTools

BOSTON--(BUSINESS WIRE)--Boston Millennia Partners (“Boston Millennia”), a significant shareholder of SomaLogic (the “Company”) (Nasdaq: SLGC) today announced that it intends to vote against the Company's planned merger (the “Merger”) with Standard BioTools Inc. (Nasdaq: LAB).

Boston Millennia Partners Intends to Vote Against Proposed Merger of SomaLogic With Standard BioTools

NEW YORK--(BUSINESS WIRE)--Madryn Asset Management, LP (collectively with its affiliates, “Madryn” or “we”), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. (“SomaLogic” or the “Company”) (Nasdaq: SLGC), today issued the following statement regarding the proposed merger (the “Proposed Merger” or the “Transaction”) with Standard BioTools Inc. (“Standard BioTools”) (Nasdaq: LAB). We would like to thank the many shareholders and stakeholders who have engaged in a.

Madryn Asset Management Highlights Increasing Public Shareholder Opposition to Value-Destructive SomaLogic Merger and Calls on Company to Make Additional Disclosures

Glass Lewis Recommendation Emphasizes Strong Strategic Rationale and Thorough Process  ISS Reiterates Recommendation Following Public Commentary Recommendations Reiterate that Value Maximizing Transaction Is in the Best Interests of Stockholders; Board Urges Stockholders to Vote "FOR" the Transaction   BOULDER, Colo. , Dec. 29, 2023 /PRNewswire/ -- SomaLogic, Inc. (Nasdaq: SLGC), a leader in proteomics technology, today announced that Glass Lewis & Co. ("Glass Lewis") has recommended that SomaLogic stockholders vote "FOR" the pending merger with Standard BioTools at the company's Special Meeting of Stockholders to be held on January 4, 2024.

Leading Independent Proxy Advisory Firms Glass Lewis and ISS Both Recommend SomaLogic Stockholders Vote "FOR" Proposed Merger with Standard BioTools

Continues to Recommend Stockholders Vote "FOR" Pending Merger ISS has Dismissed Madryn's Misleading Claims and Reaffirms that Stockholders Vote "FOR" the Merger BOULDER, Colo. , Dec. 29, 2023 /PRNewswire/ -- SomaLogic, Inc. (Nasdaq: SLGC) ("the Company"), a leader in proteomics technology, today sent the following open letter to stockholders reiterating the Board's belief that the proposed transaction between SomaLogic and Standard BioTools is in the best interest of all stockholders.

SomaLogic Board Reiterates Value-Maximizing Transaction with Standard BioTools is in Best Interests of All Stockholders

BOULDER, Colo. , Dec. 28, 2023 /PRNewswire/ -- Dr. Larry Gold, the founder of SomaLogic, Inc. ("SomaLogic" or the "Company") (Nasdaq: SLGC) and Dr. Jason Cleveland, SomaLogic's current Chief Technology Officer, are issuing the below letter to SomaLogic's stockholders regarding their opposition to the Company's proposed merger with Standard BioTools, Inc. ("Standard") (Nasdaq: LAB).

Dr. Larry Gold and Dr. Jason Cleveland Issue Open Letter to SomaLogic Stockholders Opposing SomaLogic's Proposed Merger with Standard BioTools

SomaLogic Publishes Key Correspondence from LabCorp CEO Omitted by Madryn in its Attempt to Undermine Confidence in SomaLogic's Thorough Strategic Process Reiterates Value-Maximizing Transaction with Standard BioTools is in Best Interests of All Stockholders BOULDER, Colo. , Dec. 26, 2023 /PRNewswire/ -- SomaLogic, Inc. (Nasdaq: SLGC), a leader in proteomics technology, today issued the following statement in response to a press release issued by Madryn Asset Management, LP ("Madryn") on December 26, 2023, regarding the pending merger with Standard BioTools (Nasdaq: LAB): On Christmas Eve (December 24, 2023), Madryn resorted to manufacturing rumors of a third party's interest in SomaLogic as its latest attempt to stand in the way of a Board-approved transaction.

SomaLogic Issues Statement Correcting Madryn Asset Management's Misleading Disclosure

Labcorp Holdings Inc

NEW YORK--(BUSINESS WIRE)--Madryn Asset Management, LP (collectively with its affiliates, “Madryn” or “we”), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. (“SomaLogic” or the “Company”) (Nasdaq: SLGC), today disclosed that the Transaction Committee of the Company's Board of Directors (the “Transaction Committee”) did not pursue a substantive dialogue with Laboratory Corporation of America Holdings (“Labcorp”) (NYSE: LH) – one of the industry's most logical st.

Madryn Asset Management Releases Evidence That SomaLogic Ran a Flawed and Incomplete Review of Alternatives

NEW YORK--(BUSINESS WIRE)--Madryn Asset Management, LP (collectively with its affiliates, “Madryn” or “we”), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. (“SomaLogic” or the “Company”) (Nasdaq: SLGC), today issued the following letter to Institutional Shareholder Services, Inc. (“ISS”) following ISS' publication of a report that recommends “cautionary support” for the Company's proposed merger (the “Proposed Merger”) with Standard BioTools Inc. (“Standard Bi.

Madryn Asset Management Sends Letter to ISS Respectfully Requesting it Withdraw “Cautionary Support” for SomaLogic's Value-Destructive Proposed Merger with Standard BioTools

CHARLOTTE, N.C.--(BUSINESS WIRE)--Tikvah Management (“Tikvah”), a significant shareholder of Somalogic (the “Company”) (Nasdaq: SLGC) with voting rights for 5.9 million shares, or 3.1% of the outstanding shares of Somalogic, today announced that it intends to vote against the Company's proposed merger with Standard BioTools Inc. (Nasdaq: LAB). Tikvah believes the proposed merger is not in the best interest of Somalogic shareholders, echoing reasons elaborated by other investors opposing the mer.

Tikvah Management Announces Intention to Vote against Somalogic's Proposed Merger with Standard BioTools

NEW YORK--(BUSINESS WIRE)--Madryn Asset Management, LP (“Madryn Asset Management” and, collectively with its affiliates, “Madryn” or “we”), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. (“SomaLogic” or the “Company”) (Nasdaq: SLGC), today reiterated its view that there is a viable alternative to the proposed merger (the “Proposed Merger”) with Standard BioTools Inc. (Nasdaq: LAB). Madryn issued the following statement: It is our view that SomaLogic's consider.

Madryn Asset Management Reiterates Alternative Path to SomaLogic's Value-Destructive Proposed Merger with Standard BioTools

Company Urges Stockholders to Vote “FOR” Value Maximizing Transaction at Upcoming Special Meeting Company Urges Stockholders to Vote “FOR” Value Maximizing Transaction at Upcoming Special Meeting

ISS Recommends SomaLogic Stockholders Vote “FOR” Proposed Merger with Standard BioTools

NEW YORK--(BUSINESS WIRE)--Madryn Asset Management, LP (“Madryn Asset Management” and, collectively with its affiliates, “Madryn”), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. (“SomaLogic” or the “Company”) (Nasdaq: SLGC), today commented on the additional disclosures provided late yesterday afternoon by SomaLogic related to its proposed merger (the “Proposed Merger”) with Standard BioTools Inc. (“Standard BioTools”) (Nasdaq: LAB). Madryn issued the followi.

Madryn Asset Management Highlights Newly-Disclosed Conflicts of Interest Related to Proposed SomaLogic Merger with Standard BioTools

Combination Builds Scale and Accelerates Path to Profitability, Unlocking Significant Potential Value for SomaLogic Stockholders

SomaLogic Issues Letter to Stockholders Reiterating Recommendation for Value Maximizing Merger with Standard BioTools

NEW YORK--(BUSINESS WIRE)--Madryn Asset Management, LP (“Madryn Asset Management” and, collectively with its affiliates, “Madryn”), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. (“SomaLogic” or the “Company”) (Nasdaq: SLGC), today issued a letter to shareholders to point out the numerous false and misleading statements in the investor presentation (the “SomaLogic Investor Presentation”) issued on December 19th by the Company in support of its proposed merger.

Madryn Asset Management Issues Letter to Shareholders Correcting False and Misleading Statements in SomaLogic's Recent Investor Presentation

Believes that the Proposed Merger Grossly Undervalues SomaLogic and Ignores its Revolutionary Products, Considerable Cash Position, and Strong Balance Sheet Iterates that SomaLogic can Thrive as a Standalone Enterprise and Does Not Need Standard BioTools to Thrive Expresses Serious Concerns with Other Aspects of the Proposed Merger, including Potential Conflicts of Interest BALTIMORE, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Skye Fund III, which together with its affiliates, owns approximately 3.4 million shares of SomaLogic, Inc., (NASDAQ: SLGC) (the “Company”) and has been an investor in the Company for 20 years, today issued an open letter to the Company's shareholders regarding its opposition to the Company's proposed merger (the “Proposed Merger”) with Standard BioTools Inc. (NASDAQ: LAB) and its intention to vote AGAINST the Proposed Merger at the upcoming special meeting of shareholders scheduled for January 4, 2024. The full text of the letter is set forth below: December 20, 2023 Dear Fellow Shareholders, Skye Fund III and its affiliates (collectively, “Skye”) own approximately 3.4 million shares of Common Stock, $0.0001 par value, of SomaLogic, Inc. (NASDAQ: SLGC) (“SomaLogic” or the “Company”).

Skye Fund III Issues Letter Regarding Opposition to SomaLogic's Proposed Merger with Standard BioTools

NEW YORK--(BUSINESS WIRE)--Madryn Asset Management, LP (“Madryn Asset Management” and, collectively with its affiliates, “Madryn”), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. (“SomaLogic” or the “Company”) (Nasdaq: SLGC), today issued a presentation detailing why shareholders should reject the Company's proposed merger (the “Proposed Merger”) with Standard BioTools Inc. (“Standard”) (Nasdaq: LAB). Shareholders should visit www.NoSomaLogicMerger.com for Mad.

Madryn Asset Management Issues Presentation Detailing Why SomaLogic Shareholders Should Vote “AGAINST” the Value-Destructive and Deeply Flawed Proposed Merger with Standard BioTools

NEW YORK--(BUSINESS WIRE)--Madryn Asset Management, LP (collectively with its affiliates, “Madryn”), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. (“SomaLogic” or the “Company”) (Nasdaq: SLGC), today issued an open letter to fellow shareholders regarding its opposition to the Company's proposed merger (the “Merger” or the “Combination”) with Standard BioTools Inc. (“Standard”) (Nasdaq: LAB). Additionally, Madryn announced it has filed a preliminary proxy stat.

Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of SomaLogic, Inc. (NasdaqGM: SLGC) to Standard BioTools Inc. (“the Company”) (NasdaqGS: LAB). Under the terms of the proposed transaction, upon closing of the proposed transaction, Standard BioTools shareholders will own approximately 43% of the combined company. KSF is seeking to determine whether the transacti.

STANDARD BIOTOOLS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Standard BioTools Inc. - LAB

SomaLogic Inc. (NASDAQ:SLGC ) Q3 2023 Results Conference Call November 8, 2023 4:30 PM ET Company Participants Noah Corin - IR, Gilmartin Group Adam Taich - Interim CEO Eliot Lurier - Interim Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Kyle Boucher - TD Cowen Operator Good afternoon, and welcome to SomaLogic's Third Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.

SomaLogic Inc. (SLGC) Q3 2023 Earnings Call Transcript

Expanded menu gives researchers broadest coverage of the proteome for increased discovery of biomarkers and drug targets Expanded menu gives researchers broadest coverage of the proteome for increased discovery of biomarkers and drug targets

News for SomaLogic Stock (SLGC)